BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24469255)

  • 1. Does regular zoledronic acid change the bone turnover of the jaw in men with metastatic prostate cancer: a possible clue to the pathogenesis of bisphosphonate related osteonecrosis of the jaw?
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Ristow M; Koerdt S; Schuster R; Otto S; Pautke C
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):487-93. PubMed ID: 24469255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Otto S; Pautke C
    J Oral Maxillofac Surg; 2014 May; 72(5):903-10. PubMed ID: 24485975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
    Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies.
    Bantis A; Zissimopoulos A; Sountoulides P; Kalaitzis C; Giannakopoulos S; Deftereos S; Tsakaldimis G; Thomaidis V; Touloupidis S
    Tumori; 2011; 97(4):479-83. PubMed ID: 21989437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
    Nomura T; Shibahara T; Uchiyama T; Yamamoto N; Shibui T; Yakushiji T; Watanabe A; Muramatsu K; Ogane S; Murayama M; Sekine R; Nakata E; Fujimoto Y
    Bull Tokyo Dent Coll; 2013; 54(2):117-25. PubMed ID: 23903583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies.
    Assaf AT; Smeets R; Riecke B; Weise E; Gröbe A; Blessmann M; Steiner T; Wikner J; Friedrich RE; Heiland M; Hoelzle F; Gerhards F
    Anticancer Res; 2013 Sep; 33(9):3917-24. PubMed ID: 24023329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
    O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
    J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years.
    Mücke T; Deppe H; Hein J; Wolff KD; Mitchell DA; Kesting MR; Retz M; Gschwend JE; Thalgott M
    J Craniomaxillofac Surg; 2016 Oct; 44(10):1689-1693. PubMed ID: 27555374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of bone scintigraphy in the assessment of mandibular metabolism during long-term bisphosphonate administration.
    Ohbayashi Y; Nakai F; Iwasaki A; Ogawa T; Yamamoto Y; Nishiyama Y; Miyake M
    Odontology; 2017 Jul; 105(3):382-390. PubMed ID: 27770302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bisphosphonate-induced osteonecrosis of the jaw in a patient with metastatic breast cancer].
    Amrani Raissouni T; Moya Espinosa P; Ramos Moreno E; Martínez Del Valle Torres MD; Sanz Viedma S; Ortega Lozano SJ
    Rev Esp Med Nucl; 2011; 30(5):322-3. PubMed ID: 21440957
    [No Abstract]   [Full Text] [Related]  

  • 12. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the jaw in patients with metastatic breast cancer: ethnic and socio-economic aspects.
    Quispe D; Shi R; Burton G
    Breast J; 2011; 17(5):510-3. PubMed ID: 21762241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer.
    Piccioli A
    Eur J Orthop Surg Traumatol; 2015 Jan; 25(1):29-37. PubMed ID: 24037511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) associated with a once-yearly IV infusion of zoledronic acid (Reclast) 5 mg: two cases and review of the literature.
    Katz J; Ordoveza PA
    Quintessence Int; 2014 Sep; 45(8):685-90. PubMed ID: 25019116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
    Himelstein AL; Foster JC; Khatcheressian JL; Roberts JD; Seisler DK; Novotny PJ; Qin R; Go RS; Grubbs SS; O'Connor T; Velasco MR; Weckstein D; O'Mara A; Loprinzi CL; Shapiro CL
    JAMA; 2017 Jan; 317(1):48-58. PubMed ID: 28030702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective Audit: Does Prior Assessment by Oral and Maxillofacial Surgeons Reduce the Risk of Osteonecrosis of The Jaw in Patients Receiving Bone-Targeted Therapies for Metastatic Cancers to the Skeleton?--Part II.
    Turner B; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):117-22, 132. PubMed ID: 27501592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate-related osteonecrosis of the jaws: an update on clinical, pathological and management aspects.
    Ficarra G; Beninati F
    Head Neck Pathol; 2007 Dec; 1(2):132-40. PubMed ID: 20614264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of the early stages of intravenous bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer.
    Matsuo A; Hamada H; Kaise H; Chikazu D; Yamada K; Kohno N
    Acta Odontol Scand; 2014 Nov; 72(8):656-63. PubMed ID: 24521290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Osteonecrosis of the jaw developing during bisphosphonate treatment].
    Udvardy E; Redl P; Márton I
    Magy Onkol; 2008 Mar; 52(1):81-7. PubMed ID: 18403302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.